Editorial Comment on Comparison of Perioperative Chemotherapy Regimens for Muscle‐Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials

Yusuke Goto (Sun,) reported a other. Perioperative chemotherapy regimens for muscle-invasive bladder cancer are evaluated in this editorial comment based on a reconstructed individual patient data analysis of phase 3 trials.

www.synapsesocial.com/papers/69ba431a4e9516ffd37a4065 — DOI: https://doi.org/10.1111/iju.70405

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer· 2024 · 867 citations
2. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer· 2024 · 296 citations
3. Comparison of Perioperative Chemotherapy Regimens for Muscle‐Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials· 2026 · 1 citations
4. LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study· 2025 · 32 citations
5. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma· 2023 · 453 citations